Please ensure Javascript is enabled for purposes of website accessibility

3 Things to Watch at Merrimack

By Brandy Betz - Dec 27, 2012 at 1:30PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Two promising drugs and a big pharma backer make this small cap worth noticing.

Merrimack Pharmaceuticals' (MACK -0.53%) IPO debuted with a thud this past summer, falling 14% intraday from its $7 listing price. The biopharmaceuticals company focuses on innovative treatments for serious conditions with a primary focus on cancers. The product pipeline includes a promising lead drug and a secondary drug backed by Sanofi (SNY -4.52%). But the company's trading nearly 13% below its list price.

Here are three things to watch when considering Merrimack.

1. Lead drug
MM-398 began phase 3 trials this past summer  for treatment-resistant pancreatic cancer. The Food and Drug Administration granted the drug orphan status. Additional early stage trials will examine its efficacy with colorectal cancer and gliomas -- or tumors beginning in the brain or spinal cord.

Transparency Market Research  estimates that the domestic pancreatic cancer market will hit $1.2 billion by 2015. The leading treatment has historically been Eli Lilly's (LLY 0.25%) chemo drug Gemzar. But a rising new wave of treatments, including Merrimack and Celgene's (CELG) Abraxane, offers options for patients for whom Gemzar wasn't enough .

Merrimack paid up to have a chance in this market. The company acquired MM-398's original developer in 2009 . Last year, Merrimack agreed to pay up to $220 million in up-front and milestone payments to PharmaEngine for overseas marketing rights. PharmaEngine, the drug's collaborator, will retain rights in its home country of Taiwan.

2. Secondary drug
MM-121 is involved  in three phase 2 trials, one phase 1/2 trial, and four phase 1 trials. Those trials include several types of cancers such as breast and lung. It is an ambitious drug for a small company but benefits from having Sanofi as a backer.

Sanofi made a $60 million  up-front payment and a series of milestone payments for its share of MM-121. More milestones and potential royalty payments could follow. Sanofi is responsible for the manufacturing and development costs. Merrimack will participate through phase 2 and has the option to co-promote the drug in the U.S. upon its release.

3. Cash burn
Merrimack's cash burn for the most recent quarter was around $21 million . The company reported about $87 million  in cash, cash equivalents, and short-term investments. Combine that with a new loan agreement with a $40 million limit, and Merrimack can probably sustain itself until 2014, when revenues should start flowing.

Final thoughts
It will be some time before late-stage trials report and show a clearer picture of Merrimack's standing. MM-398 will need to show strength in a market that's becoming increasingly crowded. MM-121 could become the underdog champion, especially with Sanofi's contribution. It might benefit investors to take a "wait and see" approach with Merrimack until more data arrives.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Merrimack Pharmaceuticals, Inc. Stock Quote
Merrimack Pharmaceuticals, Inc.
MACK
$5.65 (-0.53%) $0.03
Sanofi Stock Quote
Sanofi
SNY
$50.29 (-4.52%) $-2.38
Celgene Corporation Stock Quote
Celgene Corporation
CELG
Eli Lilly and Company Stock Quote
Eli Lilly and Company
LLY
$323.80 (0.25%) $0.80

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
317%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/30/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.